New data demonstrates significant and risk-appropriate clinical impact of decisiondx-scc test results on patient management decisions

Castle announced publication of an intended use survey for decisiondx®-scc for patients diagnosed with high-risk cutaneous squamous cell carcinoma.

CSTL Ratings Summary

CSTL Quant Ranking